Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

Sponsor

Virginia Commonwealth University (Other)

Overall Status

Completed

CT.gov ID

NCT02270606

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arm

77.3

Actual Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving additional combination chemotherapy after surgery may kill any remaining tumor cells. Giving radiation therapy and fluorouracil followed by combination chemotherapy before and after surgery may be a better treatment for rectal cancer.

Condition or Disease	Intervention/Treatment	Phase
Mucinous Adenocarcinoma of the Rectum Recurrent Rectal Cancer Signet Ring Adenocarcinoma of the Rectum Rectal Adenocarcinoma Stage IIA Rectal Cancer Stage IIB Rectal Cancer Stage IIC Rectal Cancer Stage IIIA Rectal Cancer Stage IIIB Rectal Cancer Stage IIIC Rectal Cancer	Radiation: intensity-modulated radiation therapy Drug: fluorouracil Drug: oxaliplatin Drug: leucovorin calcium Procedure: therapeutic conventional surgery	Phase 1

Detailed Description

OUTLINE: This is a dose-escalation study of fluorouracil.

CHEMORADIATION: Patients undergo intensity-modulated radiation therapy (IMRT) once daily (QD) over 5 days for a total of 5 fractions and concurrently receive fluorouracil intravenously (IV) continuously over 96 hours.

PREOPERATIVE CHEMOTHERAPY: Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.

SURGERY: Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision.

POSTOPERATIVE CHEMOTHERAPY: Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in preoperative chemotherapy. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year or until removal from the study or death, whichever occurs first.

Study Design

Study Type:

Interventional

Actual Enrollment :

14 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer

Actual Study Start Date :

Dec 4, 2014

Actual Primary Completion Date :

May 14, 2018

Actual Study Completion Date :

May 13, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment(IMRT,fluorouracil,chemotherapy,surgery) CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours. PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity. SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery. POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity.	Radiation: intensity-modulated radiation therapy Undergo IMRT Other Names: IMRT Drug: fluorouracil Given IV Other Names: 19893 2,4-Dioxo-5-fluoropyrimidine, 5-Fluoro-2,4(1H,3H)-pyrimidinedione, Actino-Hermal, Adrucil Arumel Drug: oxaliplatin Given IV Other Names: 1-OHP, 63121-00-6, [(1R,-2R)-1,2-cyclohexanediamine-N,N'] diaminocyclohexane oxalatoplatinum Dacotin Dacplat Drug: leucovorin calcium Given IV Other Names: 1492-18-8, 27275, 3590, 4292, 5-formyl tetrahydrofolate Adinepar calcium (6S)-folinate Calcifolin Procedure: therapeutic conventional surgery Undergo total mesorectal excision

Arm

Intervention/Treatment

Experimental: Treatment(IMRT,fluorouracil,chemotherapy,surgery)

CHEMORADIATION:Patients undergo Intensity Modulated Radiation Therapy (IMRT) once a day over 5 days for total of 5 fractions and concurrently receive fluorouracil IV continuously over 96 hours. PREOPERATIVE CHEMOTHERAPY:Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1.Treatment repeats every 14 days for 4 courses in absence of disease progression or unacceptable toxicity. SURGERY:Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision as therapeutic conventional surgery. POSTOPERATIVE CHEMOTHERAPY:Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil(preoperative chemotherapy).Treatment repeats every 14 days for 6 courses in absence of disease progression or unacceptable toxicity.

Radiation: intensity-modulated radiation therapy

Undergo IMRT

Other Names:

IMRT

Drug: fluorouracil

Given IV

Other Names:

19893

2,4-Dioxo-5-fluoropyrimidine,

5-Fluoro-2,4(1H,3H)-pyrimidinedione,

Actino-Hermal, Adrucil

Arumel

Drug: oxaliplatin

Given IV

Other Names:

1-OHP, 63121-00-6, [(1R,-2R)-1,2-cyclohexanediamine-N,N']

diaminocyclohexane

oxalatoplatinum

Dacotin

Dacplat

Drug: leucovorin calcium

Given IV

Other Names:

1492-18-8, 27275, 3590, 4292,

5-formyl tetrahydrofolate

Adinepar

calcium (6S)-folinate

Calcifolin

Procedure: therapeutic conventional surgery

Undergo total mesorectal excision

Outcome Measures

Primary Outcome Measures

Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation [Up to 21 days]
To determine the maximum tolerated dose of continuous infusional 5-Fluorouracil, up to a target dose of 200 mg/m^2/day, given concurrently with short course radiation followed by neoadjuvant FOLFOX chemotherapy and planned surgical resection for locally advanced rectal cancer. Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.

Secondary Outcome Measures

Pathological response rate for subjects treated with concurrent 5-FU [Up to at least 5 years]
To determine the rates of pathologic response for subjects treated with 5-FU together with neoadjuvant, short course pelvic RT.
Complete response rate with radiographic imaging prior to surgery [Up to 8 weeks after completion of pre-operative chemotherapy]
To determine the rate of complete response prior to surgery.
Three-year rate of local-regional recurrence for all subjects enrolled on the study [3 years]
To determine the rates of local-regional recurrence for subjects treated with 5-FU together with neoadjuvant, short course pelvic RT.
Adverse events at any time [30 days after surgery]
To determine the incidence of all toxicity (gastrointestinal and non-gastrointestinal) associated with protocol treatment in the preoperative period, the postoperative period, and therefore assess the tolerability of the combination regimen.
Three-year rate of disease-free survival for all subjects enrolled on the study [3 years]
To determine the disease-free survival for subjects treated with 5-FU together with neoadjuvant, short course pelvic RT.
Postoperative morbidity rates [Up to 30 days after surgery]
Postoperative mortality rates [Up to 30 days after surgery]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Pathologically proven diagnosis of adenocarcinoma of the rectum (located below the peritoneal reflection or begins within 15 cm of the anal verge on flexible endoscopy) within 90 days of registration; diagnosis of rectal adenocarcinoma must be obtained by biopsy technique that does not completely excise the lesion (eg, fine needle aspiration, core needle biopsy)
Clinically determined to be clinically staged (American Joint Committee on Cancer (AJCC) 7th edition [ed.]) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup within 90 days prior to registration:
Colonoscopy
History/physical examination (including medication history screen for contraindications)
Contrast-enhanced imaging of the abdomen and pelvis either by computed tomography (CT), magnetic resonance imaging (MRI), or whole body positron emission tomography (PET)-CT (preferred)
Chest x-ray (or CT) of the chest to exclude distant metastases (except for those who have had whole body PET-CT per above bullet point)
Transrectal ultrasound (TRUS) or MRI for T staging
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
Platelets >= 100,000 cells/mm^3
Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable)
Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN)
Alkaline phosphatase < 2.5 x ULN
Bilirubin =< 1.5 ULN
Calculated creatinine clearance (CrCl) > 50 mL/min using Cockcroft-Gault formula
Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation
Must provide study-specific informed consent prior to study entry
Must have a negative serum pregnancy test

Exclusion Criteria:

Prior radiotherapy to the region of the body that would result in overlap of RT fields with the current protocol treatment
Severe, active comorbidity, defined as follows:
Unstable angina and/or congestive heart failure requiring hospitalization within the last 12 months
Transmural myocardial infarction within the last 6 months
Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration
Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
Evidence of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of treatment protocol or follow up
Known, existing uncontrolled coagulopathy; subjects on therapeutic anticoagulation may be enrolled provided that they have been clinically stable on anti-coagulation for at least 2 weeks
Major surgery within 28 days of study enrollment (other than diverting colostomy)
Crohn's disease or ulcerative colitis requiring hospitalization, surgery or immunosuppressive medications
Prior allergic reaction to 5-Fluorouracil or oxaliplatin
Any evidence of distant metastases (M1)
Extension of malignant disease into the anal canal
Pregnant as determined by a positive serum pregnancy test within 14 days prior to registration on study (for females of childbearing potential)